Answers are grounded in this paper and cite their sources.
Goal:Monitoring the genetic diversity and emerging mutations of SARS-CoV-2 is crucial for understanding the evolution of the virus and assuring the performance of diagnostic tests, vaccines, and therapies against COVID-19. SARS-CoV-2 is still adapting to humans and, as illustrated by B.1.1.7 (Alpha) and B.1.617.2 (Delta), lineage dynamics are fluid, and strain prevalence may change radically in a matter of months. The National Institutes of Health's Rapid Acceleration of Diagnostics (RADxSM) initiative created a Variant Task Force to assess the impact of emerging SARS-CoV-2 variants onin vitrodiagnostic testing. Working in tandem with clinical laboratories, the FDA, and the CDC, the Variant Task Force uses bothin silicomodeling andin vitrotesting to determine the effect of SARS-CoV-2 mutations on diagnostic molecular and antigen tests. Here, we offer an overview of the approach and activities of the RADx Variant Task Force to ensure test performance against emerging SARS-CoV-2 lineages.
No takes yet. Share an insight, caveat, or question.
Creager et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: